Interferon therapy in recurrent renal carcinoma.
Seven patients with recurrent renal carcinoma, who had previously been treated with progesterone and vinblastine for progressive disease, were treated with human leukocyte interferon (HuIFN alpha). Five patients received daily escalating i.m. IFN doses from 4 X 10 up to 16 X 10(6) U during a minimum of 4 weeks, while two patients received intralesional IFN, 20 X 10(6) U/dose. No serious side-effects were observed. No tumor response was found in any of these patients.
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D007962:Leukocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*
D007372:Interferons